Clinical trials: GVHD
Chronic Graft-versus-host Disease
MSC for Treatment of cGVHD After Allo-HSCT
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
- Trial name
- NCT04692376
- Testing
- Mesenchymal stem cells, Glucocorticoids, cyclosporine
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Graft Versus Host Disease, Lymphoma
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells.
- Trial name
- NCT00003414
- Testing
- aldesleukin, recombinant interferon gamma, busulfan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Migraine, Healthy
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects.
- Trial name
- NCT01970943
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Graft Versus Host Disease, Leukemia
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002833
- Testing
- Filgrastim, Cladribine, Cyclosporine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Ankle Instability
Comparing Manipulation and Rehabilitation to Rehabilitation Only, in the Management of Chronic Ankle Instability
It is hypothesized that a combination approach would produce increased clinically and statistically significant outcomes as opposed to standard single intervention, inclusive of comparatively greater reduction in pain…
- Trial name
- NCT01196949
- Testing
- Manipulative and Rehabilitative Therapy, Rehabilitative Therapy
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- Cleveland Chiropractic College
Chronic Graft Versus Host Disease
Multiple Donor Treg DLI for Severe Refractory Chronic GVHD
This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS. The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC…
- Trial name
- TREG2015001 (NCT02749084)
- Testing
- T reg DLI
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Mario Arpinati
Leukemia
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia.
- Trial name
- NCT01517347
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University People's Hospital
Graft Versus Host Disease, Extracorporeal Photopheresis
Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease
Extracorporeal photopheresis (ECP) is a cellular therapy indicated in the treatment of chronic GVHD (cGVHD). In this study protocol, patients suffering from inaugural cGVHD will be treated with the association of ECP and…
- Trial name
- IMMUNO-PEC (NCT03438643)
- Testing
- Blood samples, skin biopsy
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Lille
Graft Versus Host Disease, Postbiotics
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
Hematopoietic stem cell transplantation consists of preconditioning chemotherapy, stem cell infusion, and engraftment of hematopoietic stem cells.
- Conditions
- Graft Versus Host Disease, Postbiotics, Butyrate
- Trial name
- NCT05808985
- Testing
- sodium butyrate
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Soonchunhyang University Hospital
Graft Versus Host Disease, Hyperkalemia
Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair
Blood transfusions are required for patients undergoing a craniosynostosis repair due to the significant amount of blood loss. Irradiated or non-irradiated transfusions have many risks involved including elevated potassium levels…
- Conditions
- Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy
- Trial name
- NCT02483702
- Testing
- Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Valley Anesthesiology Consultants
Graft-versus-Host Disease (GVHD), Hematologic Malignancies
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing…
- Conditions
- Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
- Trial name
- GVHD-PTCy (NCT06926595)
- Testing
- Cyclophosphamide (primary intervention for GVHD prophylaxis)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Chagas' Disease (Chronic) With Other Organ Involvement
Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation
Chagas disease is one of the most neglected vector-borne infectious disease worldwide. The first decades following the discovery of the pathology drove an international research enthusiasm, mainly concentrated on understanding…
- Trial name
- NCT03189056
- Testing
- Chagas serology, Creatinina, Urodynamic exploration
- Where
- Bolivia
- Volunteers
- 152 people
- Sponsor
- Institut de Recherche pour le Developpement
CMV Infection or Reactivation After Allogenic HSCT
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant…
- Trial name
- CMV (NCT06362720)
- Volunteers
- 158 people
- Sponsor
- Siriraj Hospital
Hypertensive Intracerebral Hemorrhage
Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage
Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage for Accelerating Functional Rehabilitation (RESCUE-CHAIN): a Multi-center Randomized Controlled Trial
- Trial name
- NCT04957862
- Testing
- Robotic Assisted Evacuation
- Volunteers
- 428 people
- Sponsor
- Shanghai Changzheng Hospital
Gingivitis, Gingivitis; Chronic
A Multicentre Randomised Controlled Trial Evaluating the Efficacy of the SMILE™ Module for Improving Short-term Periodontal Outcomes, Compliance, and Acceptability Among Clinical Dental Students
This multicentre randomised controlled trial aims to evaluate the efficacy and safety of the SMILETM (Siwak Method for Integrated Lifestyle Enhancement) module in improving short-term periodontal outcomes, oral hygiene behaviour…
- Trial name
- SMILE (NCT07702383)
- Testing
- SMILE Module, Conventional Toothbrushing Module
- Where
- 4 sites in Malaysia
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Graft vs Host Disease
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
In this study, a combination of two antibodies both conjugated to a cell-killing toxin (so-called immunotoxins) will be evaluated.
- Trial name
- NCT02027805
- Testing
- T-Guard
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Xenikos
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.